Pharmacy lobby pits House against Senate in debate over coverage of dual eligibles

Share this article:
Average Medicare Part D monthly premium to rise by $3 in 2009
Average Medicare Part D monthly premium to rise by $3 in 2009
Dual-eligible seniors are caught in a Capitol Hill cross fire over a pledge from the pharmaceutical industry to reduce costs by $80 billion, according to reports from Washington.

Under a House Energy and Commerce Committee proposal from Chairman Henry Waxman (D-CA), the pharmaceutical industry would reinstitute a rebate it initially offered Medicaid for dual-eligible beneficiary coverage when the Medicare Part D program took effect. That rebate—34%—is significantly higher than the 14% rebate the industry now offers Medicare Part D for dual eligibles. It could bring up to $86 billion in savings over the next ten years, according to a study put out by Waxman. The industry calls any such rebates a big step backward, Politico.com reported. Dual eligibles, who are eligible for both Medicare and Medicaid, make up a significant portion of the nursing home resident population.

By striking an early deal with Senate Finance Committee Chairman Max Baucus (D-MT) to reduce costs by $80 billion, the Pharmaceutical Research and Manufacturers Association (PhRMA) hopes to convince House lawmakers to kill the Waxman proposal before it even passes the House, according to the Web site. Baucus helped PhRMA shift dual-eligible coverage from Medicaid (at the 34% discount) to Medicare Part D (at the 14% discount) in 2006, Politico.com reported. 
Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.